Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 6/20 | 1.00 |
| ▸ | G6PD | P11413 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 4/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | GABRP | O00591 | 2/20 | 0.70 |
| ▸ | GABRD | O14764 | 2/20 | 0.70 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.70 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.70 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.70 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.70 |
| ▸ | GABRE | P78334 | 2/20 | 0.70 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alfaxalone SCHEMBL57756 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL9436587 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL21614070 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL24766358 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL21614107 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL24675016 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL21614053 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL24765814 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL21614074 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL2111685 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119950517-A | Ganaxolone for the treatment of tuberous sclerosis | 马瑞纳斯制药公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-114828889-B | Ganaxolone for the treatment of tuberous sclerosis | 马瑞纳斯制药公司 | 2025-02-14 | — | — | CN | disclosed |
| US-11975073-B2 | Lipid prodrugs of neurosteroids | PURETECH LYT, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230181600-A1 | INJECTABLE NEUROSTEROID FORMULATIONS CONTAINING NANOPARTICLES | IMMEDICA PHARMA US INC. | 2023-06-15 | — | — | US | disclosed |
| US-20220395513-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220395513-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-4100017-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PureTech LYT, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021159021-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-3829590-A1 | LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF | PureTech LYT, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020028787-A1 | LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF | PureTech Health LLC (US) | 2020-02-06 | — | — | WO | disclosed |
| US-20070093460-A1 | Methods of using selective 11beta-HSD inhibitors to treat gluocorticoid associated states | RHODE ISLAND HOSPITAL, THE | 2007-04-26 | — | — | US | disclosed |
| US-20060228778-A1 | Novel vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof | PFIZER INC | 2006-10-12 | — | — | US | disclosed |
| US-7118885-B2 | Nucleic acid encoding vitamin D receptor related polypeptide | PFIZER INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20030032790-A1 | NOVEL VITAMIN D RECEPTOR RELATED POLYPEPTIDES, NUCLEIC ACID SEQUENCE ENCODING THE SAME AND USES THEREOF | PFIZER INC. | 2003-02-13 | — | — | US | disclosed |
| US-4950428-A | TWENTY KETO PREGNANES; PHARMACOLOGICAL PROPERTIES; STARTING MATERIALS FOR RECONSTRUCTION OF DEOXYCORTISONE CHAIN | ROUSSEL UCLAF (FR) | 1990-08-21 | — | — | US | disclosed |
| US-4847014-A | CHEMICAL INTERMEDIATES, DEHYDROHALOGENATION | ROUSSEL UCLAF (FR) | 1989-07-11 | — | — | US | disclosed |
| US-4689410-A | REACTION WITH PHOSGENE AND OZONE | ROUSSEL UCLAF (FR) | 1987-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | GABRA1 2097/4885GABRB2 2004/4885G6PD 1035/4885 |
| US-20070093460-A1 | Methods of using selective 11beta-HSD inhibitors to treat gluocorticoid associated states | HSD11B2, HSD11B1, HSD17B2 | GABRA1 522/4885GABRB2 228/4885G6PD 114/4885 |
| US-20230181600-A1 | INJECTABLE NEUROSTEROID FORMULATIONS CONTAINING NANOPARTICLES | RPS9, SCN9A, ESRRA | GABRA1 839/4885GABRB2 1528/4885G6PD 1182/4885 |
| US-20220395513-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | GABRA1 2097/4885GABRB2 2004/4885G6PD 1035/4885 |
| US-11975073-B2 | Lipid prodrugs of neurosteroids | CYP21A2, CYP46A1, CYP17A1 | GABRA1 2097/4885GABRB2 2004/4885G6PD 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.